337 related articles for article (PubMed ID: 25381384)
21. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
[TBL] [Abstract][Full Text] [Related]
22. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
[TBL] [Abstract][Full Text] [Related]
23. The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study.
Mercadante S; Ferrera P; Arcuri E
Support Care Cancer; 2011 Mar; 19(3):435-8. PubMed ID: 20882391
[TBL] [Abstract][Full Text] [Related]
24. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
Nalamachu SR; Parikh N; Dillaha L; Rauck R
J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
[TBL] [Abstract][Full Text] [Related]
25. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain.
Slatkin NE; Xie F; Messina J; Segal TJ
J Support Oncol; 2007; 5(7):327-34. PubMed ID: 17708123
[TBL] [Abstract][Full Text] [Related]
26. Opioids for the management of breakthrough pain in cancer patients.
Zeppetella G; Davies AN
Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
[TBL] [Abstract][Full Text] [Related]
27. Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients.
Kwon MY; Cho HN; Koo DH; Lee YG; Oh S; Lee SS
Korean J Intern Med; 2018 May; 33(3):577-584. PubMed ID: 28111431
[TBL] [Abstract][Full Text] [Related]
28. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management.
Fine PG; Narayana A; Passik SD
Pain Med; 2010 Jul; 11(7):1024-36. PubMed ID: 20642730
[TBL] [Abstract][Full Text] [Related]
29. Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study.
Darwish M; Kirby M; Robertson P; Tracewell W; Xie F
Clin Drug Investig; 2010; 30(6):365-73. PubMed ID: 20441245
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance.
Kaplan S; Bergamasco A; Sergerie M; Castilloux AM; Moride Y
Drug Saf; 2020 Feb; 43(2):163-177. PubMed ID: 31691255
[TBL] [Abstract][Full Text] [Related]
31. Evidence-based treatment of cancer-related breakthrough pain with opioids.
Zeppetella G
J Natl Compr Canc Netw; 2013 Mar; 11 Suppl 1():S37-43. PubMed ID: 23520185
[TBL] [Abstract][Full Text] [Related]
32. Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study.
Yen TY; Chiou JF; Chiang WY; Su WH; Huang MY; Hu MH; Wu SC; Lai YL
Medicine (Baltimore); 2018 Jul; 97(30):e11593. PubMed ID: 30045291
[TBL] [Abstract][Full Text] [Related]
33. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study.
Weinstein SM; Messina J; Xie F
Cancer; 2009 Jun; 115(11):2571-9. PubMed ID: 19373888
[TBL] [Abstract][Full Text] [Related]
34. Fentanyl buccal tablet: rapid relief from breakthrough pain.
Taylor DR
Expert Opin Pharmacother; 2007 Dec; 8(17):3043-51. PubMed ID: 18001263
[TBL] [Abstract][Full Text] [Related]
35. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
Alberts DS; Smith CC; Parikh N; Rauck RL
Pain Manag; 2016 Oct; 6(5):427-34. PubMed ID: 27020837
[TBL] [Abstract][Full Text] [Related]
36. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain.
Zeppetella G; Messina J; Xie F; Slatkin NE
Pain Pract; 2010; 10(4):287-93. PubMed ID: 20230447
[TBL] [Abstract][Full Text] [Related]
37. A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan.
Chiou TJ; Chao TC; Chao TY; Huang JS; Chang YF; Wang CH
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1179. PubMed ID: 32721110
[TBL] [Abstract][Full Text] [Related]
38. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain.
Webster LR; Messina J; Xie F; Nalamachu S
J Opioid Manag; 2011; 7(4):297-308. PubMed ID: 21957829
[TBL] [Abstract][Full Text] [Related]
39. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.
Christie JM; Simmonds M; Patt R; Coluzzi P; Busch MA; Nordbrock E; Portenoy RK
J Clin Oncol; 1998 Oct; 16(10):3238-45. PubMed ID: 9779697
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Hashemi M; Zali A; Golmakani E; Delshad MH; Shadnoush M; Akbari ME
Daru; 2021 Jun; 29(1):51-59. PubMed ID: 33475984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]